May 29 |
ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer
|
May 28 |
EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24
|
May 21 |
Insider Stock Buying Reaches US$709.0k On ESSA Pharma
|
May 14 |
ESSA Pharma GAAP EPS of -$0.20 misses by $0.01
|
May 14 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
|
Apr 9 |
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
Apr 8 |
ESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its Business
|